Gastrointestinal stromal tumour

[1]  A. Agaimy,et al.  Lymph node metastasis in gastrointestinal stromal tumours (GIST) occurs preferentially in young patients ≤40 years: an overview based on our case material and the literature , 2009, Langenbeck's Archives of Surgery.

[2]  C. Antonescu,et al.  Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  K. Owzar,et al.  Correlation of kinase genotype and clinical outcome in the North American Intergroup Phase III Trial of imatinib mesylate for treatment of advanced gastrointestinal stromal tumor: CALGB 150105 Study by Cancer and Leukemia Group B and Southwest Oncology Group. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  Narasimhan P. Agaram,et al.  Novel V600E BRAF mutations in imatinib‐naive and imatinib‐resistant gastrointestinal stromal tumors , 2008, Genes, chromosomes & cancer.

[5]  H. Joensuu.  Risk stratification of patients diagnosed with gastrointestinal stromal tumor. , 2008, Human pathology.

[6]  J. Fletcher,et al.  Heterogeneity of kinase inhibitor resistance mechanisms in GIST , 2008, The Journal of pathology.

[7]  L. Terracciano,et al.  Microscopic Gastrointestinal Stromal Tumors in Esophageal and Intestinal Surgical Resection Specimens: A Clinicopathologic, Immunohistochemical, and Molecular Study of 19 Lesions , 2008, The American journal of surgical pathology.

[8]  J. Fletcher,et al.  Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  J. Crowley,et al.  Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  C. Antonescu,et al.  Tumor mitotic rate, size, and location independently predict recurrence after resection of primary gastrointestinal stromal tumor (GIST) , 2008, Cancer.

[11]  M. Federico,et al.  Incidence and clinicopathologic features of gastrointestinal stromal tumors. A population-based study , 2007, BMC Cancer.

[12]  A. Krasinskas,et al.  “Seedling” Mesenchymal Tumors (Gastrointestinal Stromal Tumors and Leiomyomas) are Common Incidental Tumors of the Esophagogastric Junction , 2007, The American journal of surgical pathology.

[13]  C. Stratakis,et al.  Multiple gastrointestinal stromal and other tumors caused by platelet-derived growth factor receptor alpha gene mutations: a case associated with a germline V561D defect. , 2007, The Journal of clinical endocrinology and metabolism.

[14]  E. Campo,et al.  Genetics of carney triad: recurrent losses at chromosome 1 but lack of germline mutations in genes associated with paragangliomas and gastrointestinal stromal tumors. , 2007, The Journal of clinical endocrinology and metabolism.

[15]  Joseph Schlessinger,et al.  Structural Basis for Activation of the Receptor Tyrosine Kinase KIT by Stem Cell Factor , 2007, Cell.

[16]  S. Hirota,et al.  Surgical interventions for focal progression of advanced gastrointestinal stromal tumors during imatinib therapy , 2007, International Journal of Clinical Oncology.

[17]  K. Owzar,et al.  Comparison of two doses of imatinib for the treatment of unresectable or metastatic gastrointestinal stromal tumors (GIST): A meta-analyis based on 1,640 patients (pts) , 2007 .

[18]  Haesun Choi,et al.  Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  C. Antonescu,et al.  Results of Tyrosine Kinase Inhibitor Therapy Followed by Surgical Resection for Metastatic Gastrointestinal Stromal Tumor , 2007, Annals of surgery.

[20]  A. Hartmann,et al.  Minute Gastric Sclerosing Stromal Tumors (GIST Tumorlets) Are Common in Adults and Frequently Show c-KIT Mutations , 2007, The American journal of surgical pathology.

[21]  K. Ahrar,et al.  Hepatic artery chemoembolization for 110 gastrointestinal stromal tumors , 2006, Cancer.

[22]  D. Fabbro,et al.  Effects of PKC412, nilotinib, and imatinib against GIST-associated PDGFRA mutants with differential imatinib sensitivity. , 2006, Gastroenterology.

[23]  T. Nakajima,et al.  High incidence of microscopic gastrointestinal stromal tumors in the stomach. , 2006, Human pathology.

[24]  Xin Huang,et al.  Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial , 2006, The Lancet.

[25]  J. Fletcher,et al.  Molecular correlates of imatinib resistance in gastrointestinal stromal tumors. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  M. Ferrone,et al.  Functional analyses and molecular modeling of two c-Kit mutations responsible for imatinib secondary resistance in GIST patients , 2006, Oncogene.

[27]  J. Lasota,et al.  A new familial GIST identified. , 2006, The American journal of surgical pathology.

[28]  J. Fletcher,et al.  Heat shock protein 90 inhibition in imatinib-resistant gastrointestinal stromal tumor. , 2006, Cancer research.

[29]  J. Blay,et al.  Predicting toxicities for patients with advanced gastrointestinal stromal tumours treated with imatinib: a study of the European Organisation for Research and Treatment of Cancer, the Italian Sarcoma Group, and the Australasian Gastro-Intestinal Trials Group (EORTC-ISG-AGITG). , 2006, European journal of cancer.

[30]  B. Nilsson,et al.  Population‐based study of the diagnosis and treatment of gastrointestinal stromal tumours , 2006, The British journal of surgery.

[31]  R. Benjamin,et al.  New developments in gastrointestinal stromal tumor , 2006, Current opinion in oncology.

[32]  J. Zalcberg,et al.  Pathological response of gastrointestinal stromal tumour to imatinib treatment correlates with tumour KIT mutational status in individual tumour clones , 2006, Histopathology.

[33]  Y. Novitsky,et al.  Long-term Outcomes of Laparoscopic Resection of Gastric Gastrointestinal Stromal Tumors , 2006, Annals of surgery.

[34]  J. Desai,et al.  Surgical management of advanced gastrointestinal stromal tumors after treatment with targeted systemic therapy using kinase inhibitors. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[35]  A. Godwin,et al.  Therapeutic effect of imatinib in gastrointestinal stromal tumors: AKT signaling dependent and independent mechanisms. , 2006, Cancer research.

[36]  H. Joensuu,et al.  Gastrointestinal stromal tumors with KIT exon 11 deletions are associated with poor prognosis. , 2006, Gastroenterology.

[37]  J. Blay,et al.  KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours. , 2006, European journal of cancer.

[38]  J. Lasota,et al.  Gastrointestinal stromal tumors: pathology and prognosis at different sites. , 2006, Seminars in diagnostic pathology.

[39]  W. Kwan,et al.  Gastrointestinal stromal tumors in a cohort of Chinese patients in Hong Kong. , 2006, World journal of gastroenterology.

[40]  L. Sobin,et al.  Gastrointestinal Stromal Tumors of the Jejunum and Ileum: A Clinicopathologic, Immunohistochemical, and Molecular Genetic Study of 906 Cases Before Imatinib With Long-term Follow-up , 2006, The American journal of surgical pathology.

[41]  J. Blay,et al.  Gastrointestinal stromal tumours: consensus statement on diagnosis and treatment. , 2006, Canadian journal of gastroenterology = Journal canadien de gastroenterologie.

[42]  E. Willemse,et al.  Stromal Tumour of the Rectum: Laparoscopic Approach of a Rare Localization of GIST , 2006, Acta chirurgica Belgica.

[43]  L. Sobin,et al.  Gastrointestinal Stromal Tumors in Patients With Neurofibromatosis 1: A Clinicopathologic and Molecular Genetic Study of 45 Cases , 2006, The American journal of surgical pathology.

[44]  J. Blay,et al.  Management of gastrointestinal stromal tumors in the imatinib era: selected case studies. , 2006, The oncologist.

[45]  S. Mulvihill,et al.  Lessons learned from laparoscopic treatment of gastric and gastroesophageal junction stromal cell tumors , 2006, Surgical Endoscopy And Other Interventional Techniques.

[46]  S. Nguyen,et al.  Laparoscopic management of gastrointestinal stromal tumors , 2006, Surgical Endoscopy And Other Interventional Techniques.

[47]  C. Schlachta,et al.  Laparoscopic resection of gastrointestinal stromal tumors , 2006, Surgical Endoscopy And Other Interventional Techniques.

[48]  K. Sheahan,et al.  Gastrointestinal stromal tumors: insights from a new familial GIST kindred with unusual genetic and pathologic features. , 2005, The American journal of surgical pathology.

[49]  C. Osborne,et al.  Randomized, controlled trial of cyclophosphamide, methotrexate, and fluorouracil versus cyclophosphamide, doxorubicin, and fluorouracil with and without tamoxifen for high-risk, node-negative breast cancer: treatment results of Intergroup Protocol INT-0102. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[50]  J. Jónasson,et al.  Gastrointestinal stromal tumors in Iceland, 1990–2003: The Icelandic GIST study, a population‐based incidence and pathologic risk stratification study , 2005, International journal of cancer.

[51]  Greg Yothers,et al.  Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. , 2005, The New England journal of medicine.

[52]  S. Jang,et al.  Multiple gastrointestinal stromal tumors with a germline c‐kit mutation , 2005, Pathology international.

[53]  B. Eisenberg,et al.  Epidemiology of GIST. , 2005, The American journal of gastroenterology.

[54]  L. Sobin,et al.  Gastrointestinal Stromal Tumors of the Stomach in Children and Young Adults: A Clinicopathologic, Immunohistochemical, and Molecular Genetic Study of 44 Cases With Long-Term Follow-Up and Review of the Literature , 2005, The American journal of surgical pathology.

[55]  E. Wardelmann,et al.  Novel germline mutation of KIT associated with familial gastrointestinal stromal tumors and mastocytosis. , 2005, Gastroenterology.

[56]  H. Joensuu,et al.  NF1-Associated Gastrointestinal Stromal Tumors Have Unique Clinical, Phenotypic, and Genotypic Characteristics , 2005, The American journal of surgical pathology.

[57]  A. Agaimy,et al.  Gastrointestinal Stromal Tumours in Patients with Other-Type Cancer: A Mere Coincidence or an Etiological Association? A Study of 97 GIST cases , 2005, Zeitschrift fur Gastroenterologie.

[58]  M. Heinrich,et al.  PDGFRA mutations in gastrointestinal stromal tumors: frequency, spectrum and in vitro sensitivity to imatinib. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[59]  J. Blay,et al.  Outcome of patients with advanced gastro-intestinal stromal tumours crossing over to a daily imatinib dose of 800 mg after progression on 400 mg. , 2005, European journal of cancer.

[60]  C. Antonescu,et al.  A knock-in mouse model of gastrointestinal stromal tumor harboring kit K641E. , 2005, Cancer research.

[61]  J. Desai,et al.  Results from a continuation trial of SU11248 in patients (pts) with imatinib (IM)-resistant gastrointestinal stromal tumor (GIST) , 2005 .

[62]  M. Bertagnolli,et al.  Correlation of target kinase genotype with clinical activity of imatinib mesylate (IM) in patients with metastatic GI stromal tumors (GISTs) expressing KIT (KIT , 2005 .

[63]  M. Fukayama,et al.  Gastrointestinal Stromal Tumors of Neurofibromatosis Type I (von Recklinghausen's Disease) , 2005, The American journal of surgical pathology.

[64]  M. von Mehren,et al.  Gastrointestinal stromal tumors. , 2005, Hematology/oncology clinics of North America.

[65]  A. D. Van den Abbeele,et al.  Gastrointestinal stromal tumor: new nodule-within-a-mass pattern of recurrence after partial response to imatinib mesylate. , 2005, Radiology.

[66]  C. Antonescu,et al.  Acquired Resistance to Imatinib in Gastrointestinal Stromal Tumor Occurs Through Secondary Gene Mutation , 2005, Clinical Cancer Research.

[67]  M. van de Rijn,et al.  Familial gastrointestinal stromal tumor syndrome: phenotypic and molecular features in a kindred. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[68]  C. Leutner,et al.  Acquired resistance to imatinib in gastrointestinal stromal tumours caused by multiple KIT mutations. , 2005, The Lancet. Oncology.

[69]  P. Petrow,et al.  Role of computed tomography in the follow-up of hepatic and peritoneal metastases of GIST under imatinib mesylate treatment: a prospective study of 54 patients. , 2005, European journal of radiology.

[70]  I. Abdulkader,et al.  Pathological changes related to Imatinib treatment in a patient with a metastatic gastrointestinal stromal tumour , 2005, Histopathology.

[71]  N. Socci,et al.  Gastrointestinal Stromal Tumors in Children and Young Adults: A Clinicopathologic, Molecular, and Genomic Study of 15 Cases and Review of the Literature , 2005, Journal of pediatric hematology/oncology.

[72]  R. Yantiss,et al.  Multiple gastrointestinal stromal tumors in type I neurofibromatosis: a pathologic and molecular study , 2005, Modern Pathology.

[73]  B. Nilsson,et al.  Gastrointestinal stromal tumors: The incidence, prevalence, clinical course, and prognostication in the preimatinib mesylate era , 2005, Cancer.

[74]  P. Marynen,et al.  Mechanisms of resistance to imatinib mesylate in gastrointestinal stromal tumors and activity of the PKC412 inhibitor against imatinib-resistant mutants. , 2005, Gastroenterology.

[75]  I. Hernán,et al.  Novel c‐KIT germline mutation in a family with gastrointestinal stromal tumors and cutaneous hyperpigmentation , 2005, American journal of medical genetics. Part A.

[76]  K. Araki,et al.  STI571 (Glivec) inhibits the interaction between c‐KIT and heat shock protein 90 of the gastrointestinal stromal tumor cell line, GIST‐T1 , 2005, Cancer science.

[77]  L. Sobin,et al.  Gastrointestinal Stromal Tumors of the Stomach: A Clinicopathologic, Immunohistochemical, and Molecular Genetic Study of 1765 Cases With Long-term Follow-up , 2005, The American journal of surgical pathology.

[78]  H. El‐Serag,et al.  The Epidemiology of Malignant Gastrointestinal Stromal Tumors: An Analysis of 1,458 Cases from 1992 to 2000 , 2005, The American Journal of Gastroenterology.

[79]  G. Antoch,et al.  Staging and follow-up of gastrointestinal tumors with PET/CT , 2005, Abdominal Imaging.

[80]  Eric P Tamm,et al.  CT evaluation of the response of gastrointestinal stromal tumors after imatinib mesylate treatment: a quantitative analysis correlated with FDG PET findings. , 2004, AJR. American journal of roentgenology.

[81]  Rossella Bertulli,et al.  Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial , 2004, The Lancet.

[82]  J. Fletcher,et al.  Biology of gastrointestinal stromal tumors. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[83]  N. Nickl.  Gastrointestinal stromal tumors: new progress, new questions , 2004, Current opinion in gastroenterology.

[84]  Wei Zhang,et al.  A Missense Mutation in KIT Kinase Domain 1 Correlates with Imatinib Resistance in Gastrointestinal Stromal Tumors , 2004, Cancer Research.

[85]  K. Wilson,et al.  Structural Basis for the Autoinhibition and STI-571 Inhibition of c-Kit Tyrosine Kinase* , 2004, Journal of Biological Chemistry.

[86]  J. Blay,et al.  Continuous vs intermittent imatinib treatment in advanced GIST after one year: A prospective randomized phase III trial of the French Sarcoma Group , 2004 .

[87]  J. Crowley,et al.  Dose effect of imatinib (IM) in patients (pts) with metastatic GIST - Phase III Sarcoma Group Study S0033. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[88]  J. Fletcher,et al.  KIT-Negative Gastrointestinal Stromal Tumors: Proof of Concept and Therapeutic Implications , 2004, The American journal of surgical pathology.

[89]  Angela Greco,et al.  A new mutation in the KIT ATP pocket causes acquired resistance to imatinib in a gastrointestinal stromal tumor patient. , 2004, Gastroenterology.

[90]  L. Sobin,et al.  A great majority of GISTs with PDGFRA mutations represent gastric tumors of low or no malignant potential , 2004, Laboratory Investigation.

[91]  C. Ball,et al.  The novel marker, DOG1, is expressed ubiquitously in gastrointestinal stromal tumors irrespective of KIT or PDGFRA mutation status. , 2004, The American journal of pathology.

[92]  J. Fletcher,et al.  Mechanisms of oncogenic KIT signal transduction in primary gastrointestinal stromal tumors (GISTs) , 2004, Oncogene.

[93]  A. D. Van den Abbeele,et al.  NCCN Task Force report: optimal management of patients with gastrointestinal stromal tumor (GIST)--expansion and update of NCCN clinical practice guidelines. , 2004, Journal of the National Comprehensive Cancer Network : JNCCN.

[94]  M. van Glabbeke,et al.  Use of c-KIT/PDGFRA mutational analysis to predict the clinical response to imatinib in patients with advanced gastrointestinal stromal tumours entered on phase I and II studies of the EORTC Soft Tissue and Bone Sarcoma Group. , 2004, European journal of cancer.

[95]  S. Hirota,et al.  Absence of c‐kit gene mutations in gastrointestinal stromal tumours from neurofibromatosis type 1 patients , 2004, The Journal of pathology.

[96]  P. Terrier,et al.  PDGFRA germline mutation in a family with multiple cases of gastrointestinal stromal tumor. , 2004, Gastroenterology.

[97]  D. Podoloff,et al.  The role of 18F-FDG PET in staging and early prediction of response to therapy of recurrent gastrointestinal stromal tumors. , 2004, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[98]  A. D. Van den Abbeele,et al.  Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[99]  E. Wardelmann,et al.  Deletion of Trp‐557 and Lys‐558 in the juxtamembrane domain of the c‐kit protooncogene is associated with metastatic behavior of gastrointestinal stromal tumors , 2003, International journal of cancer.

[100]  S. Hirota,et al.  Gain-of-function mutations of platelet-derived growth factor receptor alpha gene in gastrointestinal stromal tumors. , 2003, Gastroenterology.

[101]  C. Antonescu,et al.  Gastrointestinal stromal tumors in a mouse model by targeted mutation of the Kit receptor tyrosine kinase , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[102]  Avijit Chakrabartty,et al.  Autoinhibition of the Kit Receptor Tyrosine Kinase by the Cytosolic Juxtamembrane Region , 2003, Molecular and Cellular Biology.

[103]  R. Schneider-Stock,et al.  High prognostic value of p16INK4 alterations in gastrointestinal stromal tumors. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[104]  Samuel Singer,et al.  PDGFRA Activating Mutations in Gastrointestinal Stromal Tumors , 2003, Science.

[105]  L. Sobin,et al.  Gastrointestinal Stromal Tumors, Intramural Leiomyomas, and Leiomyosarcomas in the Duodenum: A Clinicopathologic, Immunohistochemical, and Molecular Genetic Study of 167 Cases , 2001, The American journal of surgical pathology.

[106]  G. Demetri,et al.  Management of malignant gastrointestinal stromal tumours. , 2002, The Lancet. Oncology.

[107]  A. D. Van den Abbeele,et al.  Use of positron emission tomography in oncology and its potential role to assess response to imatinib mesylate therapy in gastrointestinal stromal tumors (GISTs). , 2002, European journal of cancer.

[108]  A. D. Van den Abbeele,et al.  Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. , 2002, The New England journal of medicine.

[109]  S. Hirota,et al.  Familial gastrointestinal stromal tumors associated with dysphagia and novel type germline mutation of KIT gene. , 2002, Gastroenterology.

[110]  J. Fletcher,et al.  Biology and genetic aspects of gastrointestinal stromal tumors: KIT activation and cytogenetic alterations. , 2002, Human pathology.

[111]  L. Sobin,et al.  Diagnosis of gastrointestinal stromal tumors: A consensus approach. , 2002, Human pathology.

[112]  M. Heinrich,et al.  KIT mutations are common in incidental gastrointestinal stromal tumors one centimeter or less in size. , 2002, The American journal of pathology.

[113]  G. Demetri,et al.  Clinical management of gastrointestinal stromal tumors: before and after STI-571. , 2002, Human pathology.

[114]  B. Druker,et al.  Inhibition of KIT tyrosine kinase activity: a novel molecular approach to the treatment of KIT-positive malignancies. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[115]  C. Stratakis,et al.  Familial paraganglioma and gastric stromal sarcoma: a new syndrome distinct from the Carney triad. , 2002, American journal of medical genetics.

[116]  C. J. Chen,et al.  KIT activation is a ubiquitous feature of gastrointestinal stromal tumors. , 2001, Cancer research.

[117]  Sigrid Stroobants,et al.  Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study , 2001, The Lancet.

[118]  T. Jacks,et al.  STI571 inactivation of the gastrointestinal stromal tumor c-KIT oncoprotein: biological and clinical implications , 2001, Oncogene.

[119]  C. Capella,et al.  Germline mutation in the juxtamembrane domain of the kit gene in a family with gastrointestinal stromal tumors and urticaria pigmentosa , 2001, Cancer.

[120]  M. Debiec‐Rychter,et al.  Chromosomal aberrations in malignant gastrointestinal stromal tumors: correlation with c-KIT gene mutation. , 2001, Cancer genetics and cytogenetics.

[121]  M. Fukayama,et al.  Mutations in c‐kit Gene Exons 9 and 13 in Gastrointestinal Stromal Tumors among Japanese , 2001, Japanese journal of cancer research : Gann.

[122]  D. Tuveson,et al.  Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. , 2001, The New England journal of medicine.

[123]  A. Kuraishi,et al.  Familial gastrointestinal stromal tumor with hyperpigmentation: association with a germline mutation of the c-kit gene. , 2001, Gastroenterology.

[124]  M. Fukayama,et al.  Allelic Loss of 14q and 22q, NF2 Mutation, and Genetic Instability Occur Independently of c‐kit Mutation in Gastrointestinal Stromal Tumor , 2000, Japanese journal of cancer research : Gann.

[125]  S. Hirota,et al.  Germline-activating mutation in the kinase domain of KIT gene in familial gastrointestinal stromal tumors. , 2000, The American journal of pathology.

[126]  L. Sobin,et al.  Gastrointestinal Stromal Tumors and Leiomyosarcomas in the Colon: A Clinicopathologic, Immunohistochemical, and Molecular Genetic Study of 44 Cases , 2000, The American journal of surgical pathology.

[127]  B. Druker,et al.  Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors. , 2000, The Journal of pharmacology and experimental therapeutics.

[128]  E. van den Berg,et al.  Soft tissue leiomyosarcomas and malignant gastrointestinal stromal tumors: differences in clinical outcome and expression of multidrug resistance proteins. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[129]  S. Knuutila,et al.  DNA sequence copy number changes in gastrointestinal stromal tumors: tumor progression and prognostic significance. , 2000, Cancer research.

[130]  Robert H Lyles,et al.  Extragastrointestinal (Soft Tissue) Stromal Tumors: An Analysis of 48 Cases with Emphasis on Histologic Predictors of Outcome , 2000, Modern Pathology.

[131]  S. Knuutila,et al.  High‐resolution deletion mapping of chromosome 14 in stromal tumors of the gastrointestinal tract suggests two distinct tumor suppressor loci , 2000, Genes, chromosomes & cancer.

[132]  Hoguen Kim,et al.  Putative chromosomal deletions on 9p, 9q and 22q occur preferentially in malignant gastrointestinal stromal tumors , 2000, International journal of cancer.

[133]  J. Fletcher,et al.  KIT extracellular and kinase domain mutations in gastrointestinal stromal tumors. , 2000, The American journal of pathology.

[134]  S. Hirota,et al.  Cause of familial and multiple gastrointestinal autonomic nerve tumors with hyperplasia of interstitial cells of Cajal is germline mutation of the c-kit gene. , 2000, The American journal of surgical pathology.

[135]  L. Sobin,et al.  Esophageal stromal tumors: a clinicopathologic, immunohistochemical, and molecular genetic study of 17 cases and comparison with esophageal leiomyomas and leiomyosarcomas. , 2000, The American journal of surgical pathology.

[136]  R. DeMatteo,et al.  Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival. , 2000, Annals of surgery.

[137]  J. Lasota,et al.  Gastrointestinal stromal tumors – definition, clinical, histological, immunohistochemical, and molecular genetic features and differential diagnosis , 2000, Virchows Archiv.

[138]  L. Sobin,et al.  Loss of heterozygosity at 1p36 predicts poor prognosis in gastrointestinal stromal/smooth muscle tumors. , 1999, Laboratory investigation; a journal of technical methods and pathology.

[139]  L. Sobin,et al.  Gastrointestinal stromal tumors/smooth muscle tumors (GISTs) primary in the omentum and mesentery: clinicopathologic and immunohistochemical study of 26 cases. , 1999, The American journal of surgical pathology.

[140]  J. Goldblum,et al.  Stromal tumors of the abdominal colon: a clinicopathologic study of 20 cases. , 1999, The American journal of surgical pathology.

[141]  J. Goldblum,et al.  Stromal tumors of the anorectum: a clinicopathologic study of 22 cases. , 1999, The American journal of surgical pathology.

[142]  J. Carney,et al.  Gastric stromal sarcoma, pulmonary chondroma, and extra-adrenal paraganglioma (Carney Triad): natural history, adrenocortical component, and possible familial occurrence. , 1999, Mayo Clinic proceedings.

[143]  L. Regan,et al.  Inhibition of Spontaneous Receptor Phosphorylation by Residues in a Putative α-Helix in the KIT Intracellular Juxtamembrane Region* , 1999, The Journal of Biological Chemistry.

[144]  L. Kapusta,et al.  Multiple familial gastrointestinal autonomic nerve tumors and small intestinal neuronal dysplasia. , 1999, The American journal of surgical pathology.

[145]  J. Lasota,et al.  Mutations in exon 11 of c-Kit occur preferentially in malignant versus benign gastrointestinal stromal tumors and do not occur in leiomyomas or leiomyosarcomas. , 1999, The American journal of pathology.

[146]  A. Kovatich,et al.  CD117: a sensitive marker for gastrointestinal stromal tumors that is more specific than CD34. , 1998, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc.

[147]  S. Hirota,et al.  Familial gastrointestinal stromal tumours with germline mutation of the KIT gene , 1998, Nature Genetics.

[148]  L. Kindblom,et al.  Gastrointestinal pacemaker cell tumor (GIPACT): gastrointestinal stromal tumors show phenotypic characteristics of the interstitial cells of Cajal. , 1998, The American journal of pathology.

[149]  S. Hirota,et al.  Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. , 1998, Science.

[150]  M. Klüppel,et al.  Developmental origin and kit‐dependent development of the interstitial cells of cajal in the mammalian small intestine , 1998, Developmental dynamics : an official publication of the American Association of Anatomists.

[151]  B. Gunawan,et al.  Cytogenetic and morphologic characteristics of gastrointestinal stromal tumors. Recurrent rearrangement of chromosome 1 and losses of chromosomes 14 and 22 as common anomalies. , 1998, Verhandlungen der Deutschen Gesellschaft fur Pathologie.

[152]  T. Terada,et al.  The gastric hypercellular microleiomyoma as a precursor lesion for clinical gastrointestinal stromal tumors. , 1997, Human pathology.

[153]  A. Odén,et al.  Malignant and benign tumors in patients with neurofibromatosis type 1 in a defined Swedish population , 1997, Cancer.

[154]  J. Goldblum,et al.  Stromal tumors of the jejunum and ileum: a clinicopathologic study of 39 cases. , 1997, The American journal of surgical pathology.

[155]  J. Tworek,et al.  Stromal tumors of the jejunum and ileum. , 1997, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc.

[156]  K. Sanders.  A case for interstitial cells of Cajal as pacemakers and mediators of neurotransmission in the gastrointestinal tract. , 1996, Gastroenterology.

[157]  S. Knuutila,et al.  DNA copy number losses in chromosome 14: an early change in gastrointestinal stromal tumors. , 1996, Cancer research.

[158]  H. Kitayama,et al.  Constitutively activating mutations of c-kit receptor tyrosine kinase confer factor-independent growth and tumorigenicity of factor-dependent hematopoietic cell lines. , 1995, Blood.

[159]  K. Min,et al.  Small intestinal stromal tumors with skeinoid fibers in neurofibromatosis: report of four cases with ultrastructural study of skeinoid fibers from paraffin blocks. , 1993, Ultrastructural pathology.

[160]  R. Pollock,et al.  Prognostic implications of patterns of failure for gastrointestinal leiomyosarcomas , 1992, Cancer.

[161]  K. Min,et al.  Small Intestinal Stromal Tumors With Skeinoid Fibers: Clinicopathological, Immunohistochemical, and Ultrastructural Investigations , 1992, The American journal of surgical pathology.

[162]  E. Atkinson,et al.  Prognostic factors influencing survival in gastrointestinal leiomyosarcomas. Implications for surgical management and staging. , 1992, Annals of surgery.

[163]  C. Heldin,et al.  Activation of the human c‐kit product by ligand‐induced dimerization mediates circular actin reorganization and chemotaxis. , 1991, The EMBO journal.

[164]  M. Mazur,et al.  Gastric stromal tumors Reappraisal of histogenesis , 1983, The American journal of surgical pathology.

[165]  L. Thuneberg.  Interstitial cells of Cajal: intestinal pacemaker cells? , 1982, Advances in anatomy, embryology, and cell biology.

[166]  G. Farr,et al.  Myosarcomas of the stomach: Natural history, prognostic factors and management , 1982, Cancer.

[167]  S. Sheps,et al.  The triad of gastric leiomyosarcoma, functioning extra-adrenal paraganglioma and pulmonary chondroma. , 1977, The New England journal of medicine.